

Secretary of State  
**NOTICE OF PROPOSED RULEMAKING\***  
A Statement of Need and Fiscal Impact accompanies this form

**FILED**  
8-1-16 2:41 PM  
ARCHIVES DIVISION  
SECRETARY OF STATE

Oregon Board of Naturopathic Medicine  
Agency and Division

---

Anne Walsh  
Rules Coordinator

---

Oregon Board of Naturopathic Medicine, 800 NE Oregon St., Suite 407, Portland, OR 97232  
Address

---

850  
Administrative Rules Chapter Number

---

(971) 673-0193  
Telephone

---

**RULE CAPTION**

Update 850-060-0226 Formulary Classifications as recommended by the Formulary Council

Not more than 15 words that reasonably identifies the subject matter of the agency's intended action.

**RULEMAKING ACTION**

Secure approval of rule numbers with the Administrative Rules Unit prior to filing

**ADOPT:**

**AMEND:**

850-060-0226

**REPEAL:**

**RENUMBER:** Secure approval of new rule numbers with the Administrative Rules Unit prior to filing.

**AMEND AND RENUMBER:** Secure approval of new rule numbers with the Administrative Rules Unit prior to filing.

**Statutory Authority:**

ORS 685.125

**Other Authority:**

**Statutes Implemented:**

ORS 685.145

**RULE SUMMARY**

Add Phenobarbital to 850-060-0226(8)(c)(D),  
and add language to 850-060-0226(26)(e) after Biologic Response Modifiers, not to be used for systemic oncology.

A public rulemaking hearing may be requested in writing by 10 or more people, or by an association with 10 or more members, within 21 days following the publication of the Notice of Proposed Rulemaking in the *Oregon Bulletin* or 28 days from the date Notice was sent to people on the agency mailing list, whichever is later. If sufficient hearing requests are received, the notice of the date and time of the rulemaking hearing must be published in the *Oregon Bulletin* at least 14 days before the hearing.

The Agency requests public comment on whether other options should be considered for achieving the rule's substantive goals while reducing negative economic impact of the rule on business.

<u>09-21-2016 3:00 p.m.</u>	<u>Anne Walsh</u>	<u>Anne.Walsh@state.or.us</u>
Last Day (m/d/yyyy) and Time for public comment	Rules Coordinator Name	Email Address

\*The Oregon Bulletin is published on the 1st of each month and updates the rule text found in the Oregon Administrative Rules Compilation.

Secretary of State  
**STATEMENT OF NEED AND FISCAL IMPACT**  
A Notice of Proposed Rulemaking accompanies this form.

**FILED**  
8-1-16 2:41 PM  
ARCHIVES DIVISION  
SECRETARY OF STATE

Oregon Board of Naturopathic Medicine  
Agency and Division

850  
Administrative Rules Chapter Number

Update 850-060-0226 Formulary Classifications as recommended by the Formulary Council

Rule Caption (Not more than 15 words that reasonably identifies the subject matter of the agency's intended action.)

In the Matter of:

850-060-0226

**Statutory Authority:**

ORS 685.125

**Other Authority:**

**Statutes Implemented:**

ORS 685.145

**Need for the Rule(s):**

to update the classification rule

**Documents Relied Upon, and where they are available:**

ORS 685 and OAR 850 <http://www.oregon.gov/obnm/Pages/ORSOAR.aspx>

**Fiscal and Economic Impact:**

n/a

**Statement of Cost of Compliance:**

**1. Impact on state agencies, units of local government and the public (ORS 183.335(2)(b)(E)):**

n/a

**2. Cost of compliance effect on small business (ORS 183.336):**

**a. Estimate the number of small business and types of businesses and industries with small businesses subject to the rule:**

n/a

**b. Projected reporting, recordkeeping and other administrative activities required for compliance, including costs of professional services:**

n/a

**c. Equipment, supplies, labor and increased administration required for compliance:**

n/a

**How were small businesses involved in the development of this rule?**

n/a

**Administrative Rule Advisory Committee consulted?:No**

**If not, why?:**

all interested parties are invited to comment

09-21-2016 3:00 p.m.	Anne Walsh	Anne.Walsh@state.or.us
Last Day (m/d/yyyy) and Time for public comment	Printed Name	Email Address

## **850-060-0226**

### **Formulary Compendium Classifications**

The Formulary Council has approved the following pharmacologic-therapeutic classifications in addition to drugs previously approved by the Formulary Council and listed in 850-060-0225. This listing does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents. The Formulary Council may consider new agents, substances and pharmacologic-therapeutic classifications for addition to this list.

- (1) Antihistamine Drugs;
  - (a) First Generation Antihistamine Drugs;
    - (A) Ethanolamine Derivatives;
    - (B) Ethylenediamine Derivatives;
    - (C) Phenothiazine Derivatives;
    - (D) Piperazine Derivatives;
    - (E) Propylamine Derivatives;
    - (F) Miscellaneous Derivatives;
  - (b) Second Generation Antihistamines.
- (2) Anti-Infective Agents;
  - (a) Anthelmintics;
  - (b) Antibacterials;
    - (A) Aminoglycosides;
    - (B) Cephalosporins;
      - (i) First Generation Cephalosporins;
      - (ii) Second Generation Cephalosporins;
      - (iii) Third Generation Cephalosporins;
      - (iv) Fourth Generation Cephalosporins.
    - (C) Miscellaneous  $\beta$ -Lactams;
      - (i) Carbacephems;
      - (ii) Carbapenems;
      - (iii) Cephamycins;
      - (iv) Monobactams.
    - (D) Chloramphenicol;
    - (E) Macrolides.
      - (i) Erythromycins;
      - (ii) Ketolides;
      - (iii) Other Macrolides.
    - (F) Penicillins;
      - (i) Natural Penicillins;
      - (ii) Aminopenicillins;
      - (iii) Penicillinase-resistant Penicillins;
      - (iv) Extended-spectrum Penicillins.
    - (G) Quinolones;
    - (H) Sulfonamides;
    - (I) Tetracyclines: Glycylcyclines;
    - (J) Antibacterials, Miscellaneous.
      - (i) Aminocyclitols;
      - (ii) Bacitracins;
      - (iii) Cyclic Lipopeptides;
      - (iv) Glycopeptides;
      - (v) Lincomycins;
      - (vi) Oxazolidinones;

- (vii) Polymyxins;
- (viii) Rifamycins;
- (ix) Streptogramins;
- (c) Antifungals;
- (A) Allylamines;
- (B) Azoles;
- (C) Echinocandins;
- (D) Polyenes;
- (E) Pyrimidines;
- (F) Antifungals, Miscellaneous.
- (d) Antimycobacterials;
- (A) Antituberculosis Agents;
- (B) Antimycobacterials, Miscellaneous.
- (e) Antivirals;
- (A) Adamantanes;
- (B) Antiretrovirals;
- (i) HIV Fusion Inhibitors;
- (ii) HIV Protease Inhibitors;
- (iii) Integrase Inhibitors;
- (iv) Nonnucleoside Reverse Transcriptase Inhibitors;
- (v) Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
- (C) Interferons;
- (D) Monoclonal Antibodies;
- (E) Neuraminidase Inhibitors;
- (F) Nucleosides and Nucleotides;
- (G) Antivirals, Miscellaneous;
- (f) Antiprotozoals;
- (A) Amebicides;
- (B) Antimalarials;
- (C) Antiprotozoals, Miscellaneous.
- (3) Antineoplastic Agents (oral and topical only) limited to the following:
  - (a) 5FU;
  - (b) Anastrozole;
  - (c) Letrozole;
  - (d) Mechlorethamine;
  - (e) Megestrol;
  - (f) Mercaptopurine;
  - (g) Methotrexate;
  - (h) Tamoxifen;
  - (i) Tretinoin.
- (4) Autonomic Drugs;
  - (a) Parasympathomimetic (Cholinergic) Agents;
  - (b) Anticholinergic Agents: Antimuscarinics/ Antispasmodics;
  - (c) Sympathomimetic (Adrenergic) Agents;
    - (A)  $\alpha$ -Adrenergic Agonists;
    - (B)  $\beta$ - Adrenergic Agonists;
      - (i) Non-selective  $\beta$ - Adrenergic Agonists;
      - (ii) Selective  $\beta_1$ - Adrenergic Agonists;
      - (iii) Selective  $\beta_2$ - Adrenergic Agonists;
    - (C)  $\alpha$ -And  $\beta$ -Adrenergic Agonists;
  - (d) Sympatholytic (Adrenergic Blocking) Agents;
  - (e) Skeletal Muscle Relaxants;

- (A) Centrally Acting Skeletal Muscle Relaxants;
- (B) Direct-acting Skeletal Muscle Relaxants;
- (C) GABA-derivative Skeletal Muscle Relaxants;
- (D) Neuromuscular Blocking Agents;
- (E) Skeletal Muscle Relaxants, Miscellaneous.
- (f) Autonomic Drugs, Miscellaneous.
- (5) Blood Derivatives.
- (6) Blood Formation, Coagulation, and Thrombosis;
  - (a) Antianemia Drugs: Iron Preparations;
  - (b) Antithrombotic Agents;
    - (A) Anticoagulants;
      - (i) Coumarin Derivatives;
      - (ii) Direct Thrombin Inhibitors;
      - (iii) Heparins;
      - (iv) Anticoagulants, Miscellaneous.
    - (B) Platelet-reducing Agents;
    - (C) Platelet-aggregation Inhibitors;
    - (D) Thrombolytic Agents;
    - (c) Hematopoietic Agents;
    - (d) Hemorrhologic Agents;
    - (e) Antihemorrhagic Agents;
      - (A) Antiheparin Agents;
      - (B) Hemostatics.
  - (7) Cardiovascular Drugs;
    - (a) Cardiac Drugs;
      - (A) Antiarrhythmic Agents;
        - (i) Class Ia Antiarrhythmics;
        - (ii) Class Ib Antiarrhythmics;
        - (iii) Class Ic Antiarrhythmics;
        - (iv) Class III Antiarrhythmics;
        - (v) Class IV Antiarrhythmics.
      - (B) Cardiotonic Agents;
      - (C) Cardiac Drugs, Miscellaneous.
    - (b) Antilipemic Agents;
      - (A) Bile Acid Sequestrants;
      - (B) Cholesterol Absorption Inhibitors;
      - (C) Fibric Acid Derivatives;
      - (D) HMG-CoA Reductase Inhibitors;
      - (E) Antilipemic Agents, Miscellaneous.
    - (c) Hypotensive Agents;
      - (A) Calcium-Channel Blocking Agents;
      - (B) Central  $\alpha$ -Agonists;
      - (C) Direct Vasodilators;
      - (D) Peripheral Adrenergic Inhibitors.
      - (d) Vasodilating Agents;
        - (A) Nitrates and Nitrites;
        - (B) Phosphodiesterase Inhibitors;
        - (C) Vasodilating Agents, Miscellaneous.
      - (e) Sclerosing Agents;
      - (f)  $\alpha$ -Adrenergic Blocking Agents;
      - (g)  $\beta$ -Adrenergic Blocking Agents;
      - (h) Calcium-Channel Blocking Agents;

- (A) Dihydropyridines;
- (B) Calcium-Channel Blocking Agents, Miscellaneous;
- (i) Renin-Angiotensin-Aldosterone System Inhibitors;
- (A) Angiotensin-Converting Enzyme Inhibitors;
- (B) Angiotensin II Receptor Antagonists;
- (C) Mineralocorticoid (Aldosterone) Receptor Antagonists;
- (D) Renin Inhibitors.
- (8) Central Nervous System Agents;
- (a) Analgesics and Antipyretics;
- (A) Nonsteroidal Anti-inflammatory Agents;
- (i) Cyclooxygenase-2 (COX-2) Inhibitors;
- (ii) Salicylates;
- (iii) Other Nonsteroidal Anti-inflammatory Agents;
- (B) Opiate Agonists;
- (C) Opiate Partial Agonists;
- (D) Analgesics and Antipyretics, Miscellaneous.
- (b) Opiate Antagonists;
- (c) Anticonvulsants;
- (A) Benzodiazepines;
- (B) Hydantoins;
- (C) Succinimides;
- (D) Anticonvulsants, Miscellaneous.
- (d) Psychotherapeutic Agents;
- (A) Antidepressants;
- (i) Monoamine Oxidase Inhibitors;
- (ii) Selective Serotonin- and Norepinephrine-reuptake Inhibitors;
- (iii) Selective Serotonin- Reuptake Inhibitors;
- (iv) Serotonin Modulators;
- (v) Tricyclics and Other Norepinephrine-reuptake Inhibitors.
- (vi) Antidepressants, Miscellaneous.
- (B) Antipsychotics.
- (e) Anorexigenic Agents and Respiratory and Cerebral Stimulants.
- (A) Amphetamines.
- (B) Anorexigenic Agents and Respiratory and Cerebral Stimulants, Miscellaneous.
- (f) Anxiolytics, Sedatives, and Hypnotics, does not include Barbiturates;
- (A) Benzodiazepines;
- (B)(i) Anxiolytics, Sedatives, and Hypnotics; Miscellaneous;
- (ii) Nitrous oxide;
- (g) Antimanic Agents;
- (h) Antimigraine Agents: Selective Serotonin Agonists;
- (i) Antiparkinsonian Agents;
- (A) Adamantanes;
- (B) Anticholinergic Agents;
- (C) Catechol-O-Methyltransferase (COMT) Inhibitors;
- (D) Dopamine Precursors;
- (E) Dopamine Receptor Agonists;
- (i) Ergot-derivative Dopamine Receptor Agonists;
- (ii) Non-ergot-derivative Dopamine Receptor Agonists;
- (F) Monoamine Oxidase B Inhibitors;
- (j) Central Nervous System Agents, Miscellaneous.
- (9) Contraceptives (foams, devices).
- (10) Diagnostic Agents.

(11) Disinfectants (for Agents used on objects other than skin).

(12) Electrolytic, Caloric, and Water Balance;

(a) Acidifying Agents;

(b) Alkalinizing Agents;

(c) Ammonia Detoxicants;

(d) Replacements Preparations;

(e) Ion-Removing Agents;

(A) Calcium-removing Agents;

(B) Potassium-removing Agents;

(C) Phosphate-removing Agents;

(D) Other Ion-removing Agents;

(f) Caloric Agents;

(g) Diuretics;

(A) Loop Diuretics;

(B) Osmotic Diuretics;

(C) Potassium-sparing Diuretics;

(D) Thiazide Diuretics;

(E) Thiazide-like Diuretics;

(F) Diuretics, Miscellaneous;

(h) Irrigation Solutions;

(i) Uricosuric Agents.

(13) Enzymes.

(14) Respiratory Tract Agents;

(a) Antihistamines;

(b) Antitussives;

(c) Anti-inflammatory Agents;

(A) Leukotriene Modifiers;

(B) Mast-cell Stabilizers;

(d) Expectorants;

(e) Pulmonary Surfactants;

(f) Respiratory Agents, Miscellaneous.

(15) Eye, Ear, Nose, and Throat (EENT) Preparations;

(a) Antiallergic Agents;

(b) Anti-infectives;

(A) Antibacterials;

(B) Antifungals;

(C) Antivirals;

(D) Anti-infectives, Miscellaneous.

(c) Anti-inflammatory Agents;

(A) Corticosteroids;

(B) Nonsteroidal Anti-inflammatory Agents;

(C) Anti-inflammatory Agents, Miscellaneous.

(d) Local Anesthetics;

(e) Mydriatics;

(f) Mouthwashes and Gargles;

(g) Vasoconstrictors;

(h) Antiglaucoma Agents;

(A)  $\alpha$ -Adrenergic Agonists;

(B)  $\beta$ -Adrenergic Agents;

(C) Carbonic Anhydrase Inhibitors;

(D) Miotics;

(E) Prostaglandin Analogs;

- (i) EENT Drugs, Miscellaneous.
- (16) Gastrointestinal Drugs;
  - (a) Antacids and Adsorbents;
  - (b) Antidiarrhea Agents;
  - (c) Antiflatulents;
  - (d) Cathartics and Laxatives;
  - (e) Cholelitholytic Agents;
  - (f) Emetics;
  - (g) Antiemetics;
  - (A) Antihistamines;
  - (B) 5-HT<sub>3</sub> Receptor Antagonists;
  - (C) Antiemetics, Miscellaneous.
  - (h) Antiulcer Agents and Acid Suppressants;
  - (A) Histamine H<sub>2</sub>-Antagonists;
  - (B) Prostaglandins;
  - (C) Protectants;
  - (D) Proton-pump Inhibitors;
  - (i) Prokinetic Agents;
  - (j) Anti-inflammatory Agents;
  - (k) GI Drugs, Miscellaneous.
- (17) Gold Compounds.
- (18) Heavy Metal Antagonists.

NOTE: IV administration requires education and training compliance with 850-060-0212.

- (19) Hormones and Synthetic Substitutes;
  - (a) Adrenals;
  - (b) Androgens;
  - (c) Contraceptives;
  - (d) Estrogens and Antiestrogens;
  - (A) Estrogens;
  - (B) Estrogen Agonists-Antagonists.
  - (e) Gonadotropins;
  - (f) Antidiabetic Agents;
  - (A)  $\alpha$ -Glucosidase Inhibitors;
  - (B) Amylinomimetics;
  - (C) Biguanides;
  - (D) Dipeptidyl Peptidase (DDP-4) Inhibitors;
  - (E) Incretin Mimetics;
  - (F) Insulins;
  - (G) Meglitinides;
  - (H) Sulfonylureas;
  - (I) Thiazolidinediones;
  - (J) Miscellaneous.
  - (g) Antihypoglycemic Agents: Glycogenolytic Agents;
  - (h) Parathyroid;
  - (i) Pituitary;
  - (j) Somatotropin Agonists and Antagonists;
  - (A) Somatotropin Agonists;
  - (B) Somatotropin Antagonists;
  - (k) Progestins;
  - (l) Thyroid and Antithyroid Agents;
  - (A) Thyroid Agents;
  - (B) Antithyroid Agents.

- (20) Local Anesthetics.
- (21) Oxytocics, except for Mifepristone.
- (22) Serums, Toxoids, and Vaccines;
  - (a) Serums;
  - (b) Toxoids;
  - (c) Vaccines.
- (23) Skin and Mucous Membrane Agents;
  - (a) Anti-infectives;
    - (A) Antibacterials;
    - (B) Antivirals;
    - (C) Antifungals;
      - (i) Allylamines;
      - (ii) Azoles;
      - (iii) Benzylamines;
      - (iv) Hydroxypyridones;
      - (v) Polyenes;
      - (vi) Thiocarbamates;
      - (vii) Antifungals, Miscellaneous.
    - (D) Scabicides and Pediculicides;
    - (E) Local Anti-infectives, Miscellaneous.
  - (b) Anti-inflammatory Agents;
  - (c) Antipruritics and Local Anesthetics;
  - (d) Astringents;
  - (e) Cell Stimulants and Proliferants;
  - (f) Detergents;
  - (g) Emollients, Demulcents, and Protectants;
  - (h) Keratolytic Agents;
  - (i) Keratoplastic Agents;
  - (j) Depigmenting and Pigmenting Agents;
    - (A) Depigmenting Agents;
    - (B) Pigmenting Agents;
  - (k) Sunscreen Agents;
  - (l) Skin and Mucous Membrane Agents, Miscellaneous.
- (24) Smooth Muscle Relaxants;
  - (a) Gastrointestinal Smooth Muscle Relaxants;
  - (b) Genitourinary Smooth Muscle Relaxants;
  - (c) Respiratory Smooth Muscle Relaxants.
- (25) Vitamins and Minerals.
- (26) Miscellaneous Therapeutic Agents;
  - (a) Alcohol Deterrents limited to the following:
    - (A) Acamprosate;
    - (B) Disulfiram;
    - (C) Naltrexone.
  - (b) 5-a Reductase Inhibitors;
  - (c) Antidotes;
  - (d) Antigout Agents;
  - (e) Biologic Response Modifiers, **not to be used for systemic oncology.**
    - (A) Interferons;
    - (B) Dimethyl Fumarate;
    - (f) Bone Resorption Inhibitors;
    - (g) Cariostatic Agents;
    - (h) Complement Inhibitors;

- (i) Disease-Modifying Antirheumatic Agents;
- (j) Gonadotropin-releasing Hormone Antagonists;
- (k) Immunosuppressive Agents;
- (l) Other Miscellaneous Therapeutic Agents limited to the following:
  - (A) Alfuzosin Hydrochloride;
  - (B) Drotrecogin Alfa (Activated);
  - (C) Lanreotide Acetate;
  - (D) Riloncept;
  - (E) Sapropterin Dihydrochloride;
  - (F) Tamsulosin Hydrochloride.

Stat. Auth.: ORS 685.125

Stats. Implemented: ORS 685.145

Hist.: BNE 1-2002, f. & cert. ef. 2-19-02; BNE 4-2002, f. & cert. ef. 8-8-02; BNE 3-2003, f. & cert. ef. 6-9-03; BNE 5-2003, f. & cert. ef. 12-5-03; BNE 5-2004, f. & cert. ef. 6-10-04; Renumbered from 850-010-0226, BNE 8-2005, f. & cert. ef. 10-27-05; BNE 9-2005, f. & cert. ef. 12-12-05; BNE 4-2006, f. & cert. ef. 12-11-06; BNE 3-2007, f. & cert. ef. 6-12-07; BNE 1-2008, f. & cert. ef. 2-19-08; BNE 2-2008, f. & cert. ef. 3-21-08; BNE 6-2008, f. & cert. ef. 6-11-08; BNE 7-2008, f. & cert. ef. 12-8-08; BNE 2-2009, f. & cert. ef. 6-17-09; BNE 7-2009, f. 12-14-09, cert. ef. 1-1-10; OBNM 5-2010, f. & cert. ef. 6-30-10; OBNM 7-2010, f. & cert. ef. 12-13-10; OBNM 2-2011, f. & cert. ef. 4-12-11; OBNM 4-2011, f. & cert. ef. 6-15-11; OBNM 3-2012, f. & cert. ef. 6-15-12; effective 4-2014